Table 1.

Published data sets used for testing the approach

Name	Topic	Number of publications	Relevant publications (%)	Reference
Appenzeller-Herzog_2020	Wilson’s Disease	3479	26 (0.75%)	[40]
Bos_2018	Cerebral small vessel disease and dementia	5756	10 (0.18%)	[41]
Donners_2021	Emicizumab	660	15 (2.27%)	[42]
Jeyaraman_2021	Osteoarthritis	1194	96 (2.26%)	[43]
Leenaars_2020	Rheumatoid arthritis	9543	792 (8.30%)	[44]
Mejboom_2021	TNFα-inhibitors and biosimilars	2224	37 (1.66%)	[45]
Muthu_2021	Spine surgery	3254	354 (10.88%)	[46]
Oud_2018	Borderline personality disorder	1053	20 (1.90%)	[47]
van_de_Schoot_2018	PTSD	6225	38 (0.61%)	[48]
Wolters_2018	Dementia and heart disease	5038	19 (0.38%)	[49]